Background: The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery.
introduction
Germ cell tumors have become the model to be considered a chemosensitive and curable neoplasm. With current multimodality therapy, a long-term disease-free status can be expected in about 80% of cases with advanced disease. In most large trials, 45%-92% of patients achieve a complete response after cisplatin-based chemotherapy alone, whereas a further 2%-33% achieve this clinical status after subsequent resection of residual metastatic deposits [1] .
The nature of post-chemotherapy tumor residuals can be determined only by excision and histological examination, but at present no consensus has been reached as to whether all patients with residual masses should undergo adjunctive surgery. Among the patients who require postchemotherapy surgery once tumor markers (AFP, b-HCG, LDH) have normalized, about 50% have only necrosis in residual masses, 35% have teratoma and approximately 15% (range 6%-37%) have residual viable malignant cells [2] . The resection of differentiated teratoma may prevent local tumor growth and late disease recurrence with possible malignant transformation [3] . In case of necrosis, patients will have no improvement of their prognosis by surgery beyond the diagnosis of a pathologic complete response (CR). For patients with viable malignant cells, the secondary resection may prolong survival depending on the biological aggressiveness of the disease, the completeness of surgery and the effectiveness of further additive treatment [4] . However, discordant histologic findings have been reported for metastases to the lung and the retroperitoneum [5, 6] . In most patients, residual masses are located in the retroperitoneal space (25%-86%) and the resection is performed as a retroperitoneal lymph node dissection or lumpectomy. Residual pulmonary nodules may be removed by thoracotomy, which is performed in approximately 10% of patients with metastatic disease [5] . These surgical procedures may be associated with long-term morbidity in some patients, even if improved tecniques are used. Therefore, attemps have been made to identify patients only presenting necrosis preoperatively to spare them the burden of unnecessary resection [3, 4] .
This report analyses long-term outcome after adjunctive surgery in patients with metastatic germ cell tumors treated with cisplatin-based chemotherapy at a single institution. and 35 of these patients (30%) underwent adjunctive surgery after cisplatinbased chemotherapy (Table 1) . Clinical restaging with CT scan of the chest and abdomen and monitoring for serum tumor markers was performed in all patients after primary chemotherapy. If serum tumor markers were still raised or failed to decrease according to the known serum half-life times, supplementary salvage chemotherapy was administered. All patients with normalized serum tumor markers who showed any evidence of residual retroperitoneal or lung masses disease or had mature teratoma in the primary tumor underwent laparotomy or thoracotomy (Table 2 ).
patients and methods

Between
All patients were explored within 8 weeks from the end of chemotherapy. All masses, regardless of their location, were resected. Further surgical margins were determinated by intraoperative frozen section analysis and if fibrotic and necrotic material was revealed with no viable tumor, a limited retroperitoneal lymphadenectomy was performed. For right-sided tumors, this included the paracaval, precaval, upper interaortocaval, upper preaortic and right iliac nodes. For left-sided tumors, the para-aortic, upper interaortocaval, upper preaortic and left iliac areas were resected. Dissection below the origin of the inferior mesenteric artery was not performed unless a palpable mass was present in this area. If the frozen section analysis demonstrated the presence of tumor (viable germ cell carcinoma or teratoma), a bilateral lymph node dissection was attempted. The ipsilateral spermatic vein was resected in all cases.
Pathology reports of the final histologic diagnoses were reviewed to determine the concordance with frozen section analyses. The pathologic specimen was classified according to the worst histologic component as necrosis, teratoma or germ cell tumor. Patients with sarcomatous or nongerminal cell elements within teratoma were included in the teratoma group.
Patients were followed every 3 months in the first and second year after surgery with physical examination and serum tumor markers. Computed tomography scans of the thorax and abdomen were obtained at 4-month intervals for the first 2 years, followed by every 6 months.
results resections after first-line chemotherapy
At the time of surgical intervention 30 patients (86%) had a partial remission with normal markers. Necrosis, differentiated teratoma and undifferentiated tumor were found in nine (30%), 19 (63%) and two (7%) of all patients (Table 3) .
In the group of 20 patients with a teratoma positive primary tumor and normal pretreatment tumor markers, nine harboured necrosis/fibrosis, nine mature teratoma and two viable cancer. The two patients with viable tumor at surgery underwent salvage chemotherapy. In 28 patients (86%), complete resection of residual tumors was achieved with one patient who underwent a resection at multiple sites. At the end of the study period, 28 patients were alive. The median observation time was 101 months (range 14-162 months). Two patients died of metastatic testicular cancer after salvage chemotherapy at 24 and 42 months from surgery.
resection after second-line chemotherapy
Five patients (14%) underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. All patients had reached a normalisation of elevated markers after second-line chemotherapy prior to the surgery. The resection was incomplete in two cases with undifferentiated tumors in resected specimens and these patients underwent further chemotherapy. The histological findings in the remaining patients were necrosis and differentiated teratoma in one and two cases, respectively (Table 3) .
After a median follow up of 86 months (range 31-124 months), three patients are alive without disease. Two patients Annals of Oncology symposium article died because of progressive disease after 70 and 125 months from the surgery.
recurrences
Five patients experienced a recurrence 1-36 months after residual resection (Table 4) . One of these experienced relapse from mature teratoma to lymph nodes outside the region of retroperitoneal lymphadenectomy. He remained without evidence of disease after surgical approach and without further chemotherapy. One patient with complete necrosis in the surgical specimen relapsed outside the lymph nodes. Three patients had shown elevated pre-residual surgery tumor markers (AFP e b-HCG). discussion Post-chemotherapy resection is an established part of the treatment in metastatic germ-cell tumors if residual tumor masses are radiologically detectable. About 15%-20% of these abnormalities will histologically contain undifferentiated tumor, 45%-50% necrotic tissue and 30%-40% mature teratoma, as recently confirmed in a report including 1000 patients from different institutions [6] after first-line chemotherapy. Retrospectively, we studied 35 patients treated with chemotherapy for metastatic GCT to assess the contribution of residual tumor resection (RTR) in the management and long-term outcome. In our series, 30 patients underwent resection of tumour residuals after the first-line chemotherapy. The surgery was complete in 28 patients. Two patients with incompletely resected masses and viable cancer underwent salvage chemotherapy. The distribution of post-chemotherapy histological findings is shown in Table 3 . Of 20 patients with teratoma-positive primary tumors and normal tumour markers at presentation, nine harboured necrosis/fibrosis at surgery, nine mature teratoma and two cases had viable tumour.
A total of 28 of 30 patients were alive without relapse. Only one patient after 36 months from retroperitoneal lymphadenectomy underwent a residual surgery for a relapse from mature teratoma. One of two patients with viable tumour is presently alive with disease-free status. The median follow-up of surviving patients was 95 months. Two patients died of metastatic disease after 24 and 42 months from the surgery. There was no surgery-related mortality.
In 1981, Einhorn et al. [7] reported that patients with undifferentiated tumor at postchemotherapy resection have a poor prognosis with a long-term survival in only two of 22 patients. In the meantime, other investigations confirmed that the use of cisplatin-based additive chemotherapy may improve the outcome of patients after the resection of vital carcinoma with 56%-70% of patients reported to be disease-free at 3 years [8] . Survival data of a total of 776 patients with metastatic nonseminomatous germ cell tumors from eight larger series undergoing surgical resections after first-line cisplatin based chemotherapy, demonstrated that between 72% and 89% of patients will remain disease-free at 3 years after surgery [6] . The finding of necrosis and/or differentiated teratoma in the resected specimens resulted in 78%-92% and 67%-95% longterm survival rate, respectively. Progression-free survival can be predicted well by the completeness of excision of residual masses and the presence of malignant germ cell elements [9] [10] [11] . The latter confers a relatively poor prognosis even if all of these elements are completely resected.
Actually, two options appear legitimate in the treatment policy for patients with postchemotherapy undifferentiated tumor: adjuvant chemotherapy immediately after resection (the classic two cycles) or surveillance with salvage chemotherapy at relapse (four cycles) [9, 10, 12, 13] .
In case of either necrosis or differentiated teratoma, no further treatment is necessary [14] . It would be useful to identify patients harbouring necrosis in residual masses prior to the operation in order to prevent surgery-related morbidity and mortality. On the other hand, surgical resection of differentiated teratoma is useful in order to prevent recurrent teratoma or a subsequent malignant transformation [15] . Microscopic residual mature teratoma after resection may grow locally at an unspecified rate and cause significant compression of adjacent structures. Such a relapse with an enlarging retroperitoneal mass after previous cisplatin-based chemotherapy without elevated serum markers a-fetoprotein (AFP) and human chorionic gonadotrophin (b-HCG) and the finding of pure mature teratoma at histologic examination was defined by Logothetis et al. in 1982 as 'growing teratoma syndrome' [16] .
Recently, Steyerberg et al. [17] performed a meta-analysis containing data from 556 patients with non-seminomatous germ cell tumors operated after first-line chemotherapy in order to develop a statistical model for the prediction of the histology of residual masses. Independent predictive factors for necrosis were the absence of teratomatous elements in the primary tumor, prechemotherapy normal AFP/b-HCG/LDH values, small pre-or postchemotherapy masses or a shrinkage of the masses >70% during chemotherapy. To distinguish undifferentiated tumor from teratoma, a higher prechemotherapy LDH level, a larger post-chemotherapy mass and a smaller relative shrinkage of the mass were of value, based on 299 patients in the second analysis. This model was useful to predict necrosis, but was less valuable for the discrimination of undifferentiated tumor from mature teratoma.
The proposed model may be helpful for the decision to operate patients immediately or to follow their residual tumors closely, dependent on the calculated risk score. However, there is a high incidence of dissimilar histologic findings (25%-47%) in resected masses from different sites in the same individual [5, 18] . A possible explanation might be that the systemic chemotherapy may have different effects on each metastatic subpopulation, depending on pharmacological characteristics of the drugs used [19] , extent of metastases, blood delivery of the affected organ and local growth conditions of tumor cells. Since the pretreatment characteristics included in the calculation of Steyerberg were certainly identical within one single patient, the observed variation of histological findings among different sites shows that the prediction of histologic results remains difficult [18, 20] .
Positron emission tomography (PET) with marked 2-fluoro-2-deoxyglucose molecules (FDG) is under investigation in patients with metastatic testicular cancer. PET-FDG imaging may be useful for the detection of residual carcinoma. However, the distinction between necrosis and differentiated teratoma may still remain difficult since both tissues have a relatively low metabolic activity. It may be speculated for patients with multiple residual masses that the combination of a negative result at PET examination at all sites and necrotic tissue found at the retroperitoneal resection may identify those patients who can be spared from resections at other sites. Another important advance for PET-FDG examination could be the identification of patients with undifferentiated tumor prior to the surgery [21] .
Patients after second-line chemotherapy had a worst prognosis [22, 23] . In our experience, one patient had pure seminoma and there were four cases of mixed histology at initial presentation. In two patients, conventional dose cisplatin, ifosfamide and vinblastine (VeIP regimen) followed by highdose chemotherapy with carboplatin, etoposide and ifosfamide (Carbo-PEC regimen) was administered as salvage treatment before RTR. All patients had residual tumour masses in the abdominal lymph-nodes. The resection was incomplete in two cases with viable cancer. After salvage chemotherapy, both of the patients relapsed with increased tumor markers and new radiologic features, and died 25 and 70 months after the surgery. The frequency of mature teratoma or viable cancer was much higher in patients after salvage high-dose chemotherapy compared with patients after first-line treatment [22, 23] . Whereas viable cancer was most often present in resected retroperitoneal residual tumors, discordant histological results were found in patients with residual tumors at multiple anatomic sites. Several groups recommended that all patients with residual tumors after high-dose chemotherapy should undergo resection of residual disease at all anatomic localizations outside the CNS [23] .
In summary, secondary resection of residual masses after first or second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. Our experience demonstrated that 69% of postchemotherapy retroperitoneal lesions contained teratoma and vital tumor and two cases with vital malignant tumor histology were >20 mm (Figure 1) .
Three parameters exert a prognostic influence in patients with postchemotherapy viable residual disease: one is related to initial tumor characteristics (the IGCCC subgroup) [24] , the second is related to both tumor behavior and the efficacy of first-line chemotherapy [25] (the proportion of viable malignant cells) and the third is related to the quality of post-chemotherapy management (namely, a complete resection) [26] . Physicians have a partial impact on the second but may optimize the third. Whereas the resection of necrosis offers no therapeutic benefit, resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients. In the future, more accurate prognostic models and the use of PET imaging might help to identify further residual undifferentiated tumors and may guide decisions about the operative procedure, particularly in patients with technically feasible operations. Annals of Oncology symposium article
